What is APUS's dilution risk score?

APUS has a latest available DilutionScore record of 67/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for APUS, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for APUS?

DilutionWatch tracks 25 SEC filing types for APUS including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect APUS shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For APUS, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for APUS tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for APUS. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

APUS Dilution Risk Score: 67/100

Score Breakdown

📋 Offering Ability

💰 Cash Runway

📊Float Risk—

⚠️ Warrant Exposure

🔄 Convertible Debt

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 42%

💰 Capital Raise model 55%

• Critical: only 1.4 months cash remaining

🔁 Convertible Conversion model 40%

• Significant convertible debt: 23% potential dilution

• Elevated convertible risk (60/100)

🔄 Reverse Split model est. 15%

• Only 1 months cash — financial pressure

🔔 Track APUS — Get forecast alerts →

Market Data

Market Cap$6.50M

Shares Outstanding1.51M

FloatN/A

Cash$1.78M

Debt$20.0K

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	67/100	DilutionWatch score record
Shares Outstanding	1.51M	Verified float table or market cache
Public Float	Not available	Verified float table or market cache
Market Cap	$6.50M	Market data cache
Cash Runway	1.4 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	111.7K	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 2.

Recent SEC source mix: XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 37.6% shares (2026Q1 vs prior)

6 institutional holders · 544.7K shares

#1 Hemenway Trust Co LLC 274.0K shares

#2 VANGUARD CAPITAL MANAGEMENT LLC 191.9K shares

#3 GEODE CAPITAL MANAGEMENT, LLC 40.1K shares

+ 3 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest79.5K

Days to Cover1.0

% of FloatN/A

FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-14

xbrl XBRL CONVERTIBLE 2026-05-04

Full SEC filing analysis available with free account →

Recent News

Why Is Apimeds Pharmaceuticals Stock Gaining Monday? Benzinga · Oct 05, 2026

Top Midday Gainers MT Newswires · Sep 24, 2026

Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon Yahoo Finance · Jul 08, 2026

Factual APUS Dilution Snapshot

Apimeds Pharmaceuticals US, Inc. (APUS) has a DilutionScore of 67/100, rated High dilution risk. Score date: October 13, 2026.

Stored outstanding warrants: 111,691.
Recent SEC activity tracked for APUS: xbrl on 2026-08-14; xbrl on 2026-05-04.
Score coverage note: Float Risk is excluded because public-float data is unavailable.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

APUS's DilutionScore is currently 67/100 (High risk), with 3 score changes tracked over 89 days. The score deteriorated from 69/100 (High risk).

Period	Score	Risk Level	Duration
Sep 28 – Oct 13, 2026	67/100	HIGH	16 days
Aug 22 – Sep 27, 2026	69/100	HIGH	37 days
Aug 14 – Aug 21, 2026	54/100	HIGH	7 days
Jul 16 – Aug 13, 2026	50/100	MEDIUM	29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Track APUS Dilution Risk in Real-Time

DilutionWatch monitors SEC filings 24/7 and alerts you the moment APUS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.

Start Tracking APUS — Free

Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education

→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

Float Risk is excluded because public-float data is unavailable.

APUS — Apimeds Pharmaceuticals US, Inc. Dilution Risk Tracker